| 1075 |
Drug-resistant TB Service Linkages to Private Sectors |
English |
Not specified |
|
Off |
| 1074 |
Mandatory Establishment of DR-TB Centres in All Medical Colleges |
English |
Not specified |
|
Off |
| 1073 |
Functions of District DR-TB Centre |
English |
Not specified |
|
Off |
| 1072 |
Requirements for Establishing District DR-TB Centres |
English |
Not specified |
|
Off |
| 1071 |
State Airborne Infection Control [AIC] Committee |
English |
Not specified |
|
Off |
| 1056 |
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen |
English |
Not specified |
|
Off |
| 1055 |
State Airborne Infection Control [AIC] Committee: Terms of Reference [ToR] |
English |
Not specified |
|
Off |
| 1054 |
State PMDT Committee: Terms of Reference [ToR] |
English |
Not specified |
|
Off |
| 1053 |
Management of Prolonged QTcF During Treatment with Shorter/Longer Oral MDR-TB Regimen |
English |
Not specified |
|
Off |
| 1052 |
Management of QT Prolongation by Grade of Severity of ADR |
English |
Not specified |
|
Off |
| 1051 |
Common or Relevant Adverse Effects of DR-TB Therapy |
English |
Not specified |
|
Off |
| 1050 |
Immune Reconstitution Inflammatory Syndrome [IRIS] |
English |
Not specified |
|
Off |
| 1049 |
DR-TB Treatment in Pregnancy: General Considerations |
English |
Not specified |
|
Off |
| 1048 |
Shorter Injectable-containing MDR/RR-TB Regimen: Pre-treatment evaluation and follow-up |
English |
Not specified |
|
Off |
| 1038 |
Pre-treatment Evaluation [PTE] of DR-TB Patients |
English |
Not specified |
|
Off |
| 1036 |
Key Messages for TB Counselling |
English |
Not specified |
|
Off |
| 1035 |
Components of Drug Resistant TB Counselling Tool |
English |
Not specified |
|
Off |
| 1032 |
Delamanid [Dlm] Drug Dosages and Duration |
English |
Not specified |
|
Off |
| 1031 |
Eligibility Criteria for the Use of Delamanid [Dlm] in MDR/RR-TB Treatment |
English |
Not specified |
|
Off |
| 1030 |
Bedaquiline Drug Dosages and Duration |
English |
Not specified |
|
Off |
| 1029 |
Eligibility Criteria for the Use of Bedaquiline [Bdq] in MDR/RR-TB Treatment |
English |
Not specified |
|
Off |
| 1028 |
Drugs Not Included in Groups A - C and Rationale for Non-inclusion |
English |
Not specified |
|
Off |
| 1027 |
Rationale for Grouping of Anti-TB Drugs |
English |
Not specified |
|
Off |
| 1026 |
Drugs Used in the Management of Adverse Events |
English |
Not specified |
|
Off |
| 1018 |
Role of the State Drug Store [SDS] in the Constitution of Patient-wise Boxes |
English |
Not specified |
|
Off |
| 1017 |
Guidelines for Issuing Bedaquiline and Delamanid to the Patient |
English |
Not specified |
|
Off |
| 1016 |
Constituents of Patient-wise Boxes [PWB] for Isoniazid [H] Mono/Poly DR-TB Regimen |
English |
Not specified |
|
Off |
| 1012 |
Management of DR-TB Patients: Lost to Follow-up |
English |
Not specified |
|
Off |
| 1011 |
Management of DR-TB ADR: Gynecomastia |
English |
Not specified |
|
Off |
| 1010 |
Management of DR-TB ADR: Nephrotoxicity [Renal Toxicity] |
English |
Not specified |
|
Off |
| 1009 |
Management of DR-TB ADR: Seizures |
English |
Not specified |
|
Off |
| 1008 |
Management of DR-TB ADR: Suicidal Ideation |
English |
Not specified |
|
Off |
| 1007 |
Management of DR-TB ADR: Psychotic Symptoms |
English |
Not specified |
|
Off |
| 1006 |
Management of DR-TB ADR: Depression |
English |
Not specified |
|
Off |
| 1005 |
Management of DR-TB ADR: Arthralgia |
English |
Not specified |
|
Off |
| 1004 |
Management of DR-TB ADR: Hypothyroidism |
English |
Not specified |
|
Off |
| 1003 |
Management of DR-TB ADR: Hematological Abnormalities |
English |
Not specified |
|
Off |
| 1002 |
Management of DR-TB ADR: Giddiness |
English |
Not specified |
|
Off |
| 1001 |
Management of DR-TB ADR: Diarrhoea and/or Flatulence |
English |
Not specified |
|
Off |
| 1000 |
Management of DR-TB ADR: Gastritis, abdominal pain |
English |
Not specified |
|
Off |
| 986 |
Treatment Extension in Isoniazid [H] Mono/Poly DR-TB Regimen |
English |
Not specified |
|
Off |
| 985 |
Eligibility Criteria for Longer Oral M/XDR-TB Regimen |
English |
Not specified |
|
Off |
| 982 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Pre-existing Liver Disease |
English |
Not specified |
|
Off |
| 981 |
Use of Shorter Oral Bedaquiline-containing MDR/RR-TB Regimen in Special Situations |
English |
Not specified |
|
Off |
| 978 |
List of Drugs that can be Used Safely or Avoided along with Bedaquiline |
English |
Not specified |
|
Off |
| 976 |
Second Line anti TB drugs |
English |
Not specified |
|
Off |
| 974 |
Sustainable Development Goals [SDGs] related to TB |
English |
Not specified |
|
Off |
| 972 |
Principles of Preparing a realistic ACSM budget |
English |
Not specified |
|
Off |
| 971 |
Budget Heads related to NTEP activities across NHM PIP |
English |
Not specified |
|
Off |
| 970 |
ACSM planning based on needs assessment |
English |
Not specified |
|
Off |
